{
  "pmcid": "6365260",
  "sha256": "4cbbd125c07bfc77625cb8372fd46f7cc4a293cad1e00524d4322232dcd93e60",
  "timestamp_utc": "2025-11-10T00:01:28.261929+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.103178947368423,
    "reading_ease": 31.724536842105294,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial Comparing Partial and Circumferential Stapled Hemorrhoidopexy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "single-center, parallel-group, randomised, noninferiority trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "300 patients with grade III/IV hemorrhoids were recruited between August 2011 and November 2013"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned in a 1:1 ratio to receive either PSH (n = 150) or CSH (n = 150)"
      },
      "Objective": {
        "score": 1,
        "evidence": "The long-term outcomes of partial stapled hemorrhoidopexy (PSH) versus circumferential stapled hemorrhoidopexy (CSH) for grade III/IV hemorrhoids remain unclear."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the rate of recurrent prolapse at a median follow-up of 5 years"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "blocked randomisation with a fixed block size of 4. Allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Patients and outcome assessors were blinded to the intervention."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "300 patients with grade III/IV hemorrhoids were recruited between August 2011 and November 2013"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "PSH (n = 150) or CSH (n = 150)"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 5-year cumulative recurrence rate was 9% (95% CI, 4%–13%) for PSH and 12% (95% CI, 7%–17%) for CSH (p = 0.137)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were minimal, with no rectovaginal fistulas reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: chiCTR-trc-11001506."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}